Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar cardiovascular outcomes study after acute coronary syndrome in type 2 diabetes
NL-OMON36231Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) comparing Aleglitazar + background care with Placebo + background care (2 arms). Planned start Feb 2010; status: withdrawn.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NL-OMON36231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36231.